Printer Friendly

Ocata Therapeutics to be acquired by Astellas Pharma.

M2 EQUITYBITES-November 11, 2015-Ocata Therapeutics to be acquired by Astellas Pharma

(C)2015 M2 COMMUNICATIONS http://www.m2.com

Astellas Pharma, a Japan-based drug company, has agreed to acquire Ocata Therapeutics, a United States-based clinical stage biotechnology company, it was reported yesterday.

The deal is valued at USD379m. Astellas will make a tender offer worth USD8.50 a share in cash to buy Ocata.

Ocata develops and commercialises regenerative ophthalmology therapeutics. The company's principal R&D and commercial efforts relate to its Regenerative Ophthalmology programs and involves development of therapies to treat eye diseases and disorders. The transaction is intended to enable Astellas to establish a presence in ophthalmology and advance in the field of cell therapy.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Nov 11, 2015
Words:128
Previous Article:Nicox signs license agreement with Fera Pharmaceuticals.
Next Article:Morgan Stanley Income Securities announces monthly income dividend of USD0.045 per share.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |